GTHR Stock Overview
A biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
GeneThera, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.006 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 3 Year Change | -99.86% |
| 5 Year Change | -96.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| GTHR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.2% | 0.7% |
| 1Y | n/a | -7.0% | 23.0% |
Return vs Industry: Insufficient data to determine how GTHR performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how GTHR performed against the US Market.
Price Volatility
| GTHR volatility | |
|---|---|
| GTHR Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GTHR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine GTHR's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Tony Milici | www.genethera.net |
GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. It offers treatments for zoonotic diseases, such as COVID -19 disease; paratuberculosis (Johne’s disease) that is in Stage III clinical phase; mad cow and chronic wasting diseases; and E.coli and salmonella infections, as well as develops vaccine for mycobacterium avium sub paratuberculosis bacteria. The company’s Molecular Robotic/AI Platform and Therapeutic strategy is designed to prevent the spread of disease from animals and allow to better control of zoonotic infectious agents.
GeneThera, Inc. Fundamentals Summary
| GTHR fundamental statistics | |
|---|---|
| Market cap | US$3.53k |
| Earnings (TTM) | -US$681.26k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs GTHR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GTHR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$681.26k |
| Earnings | -US$681.26k |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did GTHR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/22 15:17 |
| End of Day Share Price | 2024/07/25 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GeneThera, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|